OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 4, 2022
PDF Version 367.9 KB
Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today announces its management will present and meet with investors at the H.C. Wainwright BioConnect 2022 Virtual Conference:
H.C. Wainwright BioConnect 2022 Virtual Conference |
January 10-13, 2022 |
Pre-recorded CEO Presentation available starting on January 10 at 7:00 AM ET |
For more information, please visit Oxurion's events page